Encorafenib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 495 publications
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.
Journal: Future oncology (London, England)
Published: March 31, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Journal: Future oncology (London, England)
Published: March 30, 2026
A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary.
Journal: Future oncology (London, England)
Published: March 24, 2026
Prolonged response to Pembrolizumab in BRAFV600E microsatellite stable metastatic colorectal cancer following an increase in tumour mutational burden.
Journal: The oncologist
Published: March 09, 2026
Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: February 22, 2026
Real-world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: the COALA project.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib.
Journal: Journal of clinical medicine
Published: February 04, 2026
Remission of metastatic duodenal cancer after treatment with BRAF inhibitor
Journal: Ugeskrift for laeger
Published: January 30, 2026
Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study.
Journal: The oncologist
Published: January 20, 2026
Dual Targeting of Akt and MAPK Pathways With Capivasertib and B-Raf Inhibitors Synergistically Suppresses Tumor Growth in B-Raf-Mutated Melanoma Models.
Journal: Fundamental & clinical pharmacology
Published: January 14, 2026
Last Updated: 06/30/2026